Abbott Laboratories' (NYSE:ABT) finds itself at #14 for research and development budget with $1.71 bn EUR and #9 for sales in 2006. Abbott did issue a recall on 
blood pressure monitors in September and received FDA approval for Niaspan indicated as a medication in boosting HDL (good) cholesterol but overall has had a lackluster year. Currently it has 4 drugs in Phase III trials.
Phase III Pipeline:
Adalimumab (Humira) - Rheumatoid Arthritis, Crohn's Disease, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile RA, Ulcerative Colitis, Uveitis, Giant Cell Arteritis
Levosimendan - Congestive heart failure, Acute Heart Failure, Cardiogenic Shock, Septic Shock
ABT-335 androsuvastatin calcium - Hypercholesterolemia, Dyslipidemia
Atrasentan - Cancer, Prostatic Neoplasms Pricalcitol - Chronic Renal Insufficiency
[Source: FierceBioTech]
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 14, 2007 2:18 PM | Permalink to Trackback